Rapid Eye Movement Sleep Behavior Disorder: Abnormal Cardiac Image and Progressive Abnormal Metabolic Brain Pattern.
[123I]MIBG scintigraphy
[18F]FDG-PET-derived Parkinson's disease-related pattern
hyposmia
isolated rapid eye movement sleep behavior disorder
prodromal progression biomarker
Journal
Movement disorders : official journal of the Movement Disorder Society
ISSN: 1531-8257
Titre abrégé: Mov Disord
Pays: United States
ID NLM: 8610688
Informations de publication
Date de publication:
03 2022
03 2022
Historique:
revised:
29
10
2021
received:
02
07
2021
accepted:
29
10
2021
pubmed:
20
11
2021
medline:
3
5
2022
entrez:
19
11
2021
Statut:
ppublish
Résumé
Isolated rapid eye movement sleep behavior disorder (iRBD) is prodromal for α-synucleinopathies. The aim of this study was to determine whether pathological cardiac [ Seventeen subjects with iRBD underwent [ Twelve of 17 subjects had pathological [ Pathological [
Sections du résumé
BACKGROUND
Isolated rapid eye movement sleep behavior disorder (iRBD) is prodromal for α-synucleinopathies.
OBJECTIVE
The aim of this study was to determine whether pathological cardiac [
METHODS
Seventeen subjects with iRBD underwent [
RESULTS
Twelve of 17 subjects had pathological [
CONCLUSIONS
Pathological [
Substances chimiques
3-Iodobenzylguanidine
35MRW7B4AD
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
624-629Informations de copyright
© 2021 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
Références
Schenck CH, Boeve BF, Mahowald MW. Delayed emergence of a parkinsonian disorder or dementia in 81% of older men initially diagnosed with idiopathic rapid eye movement sleep behavior disorder: a 16-year update on a previously reported series. Sleep Med 2013;14(8):744-748.
Iranzo A, Fernández-Arcos A, Tolosa E, et al. Neurodegenerative disorder risk in idiopathic REM sleep behavior disorder: study in 174 patients. PLoS One 2014;9(2):e89741
Postuma RB, Iranzo A, Hu M, et al. Risk and predictors of dementia and parkinsonism in idiopathic REM sleep behaviour disorder: a multicentre study. Brain 2019;142(3):744-759.
Miyamoto T, Miyamoto M, Iwanami M, et al. Olfactory dysfunction in idiopathic REM sleep behavior disorder. Sleep Med 2010;11(5):458-461.
Stiasny-Kolster K, Doerr Y, Möller JC, et al. Combination of ‘idiopathic’ REM sleep behaviour disorder and olfactory dysfunction as possible indicator for alpha-synucleinopathy demonstrated by dopamine transporter FP-CIT-SPECT. Brain 2005;128(Pt 1):126-137.
Kashihara K, Imamura T, Shinya T. Cardiac 123I-MIBG uptake is reduced more markedly in patients with REM sleep behavior disorder than in those with early stage Parkinson's disease. Parkinsonism Relat Disord 2010;16(4):252-255.
Miyamoto T, Miyamoto M, Iwanami M, Hirata K. Follow-up study of cardiac 123I-MIBG scintigraphy in idiopathic REM sleep behavior disorder. Eur J Neurol 2011;18(10):1275-1278.
Iranzo A, Santamaría J, Valldeoriola F, et al. Dopamine transporter imaging deficit predicts early transition to synucleinopathy in idiopathic rapid eye movement sleep behavior disorder. Ann Neurol 2017;82(3):419-428.
Arnaldi D, Chincarini A, Hu MT, et al. Dopaminergic imaging and clinical predictors for phenoconversion of REM sleep behaviour disorder. Brain 2021;144(1):278-287.
Meles SK, Vadasz D, Renken RJ, et al. FDG PET, dopamine transporter SPECT, and olfaction: combining biomarkers in REM sleep behavior disorder. Mov Disord 2017;32(10):1482-1486.
Meles SK, Renken RJ, Janzen A, et al. The metabolic pattern of idiopathic REM sleep behavior disorder reflects early-stage Parkinson disease. J Nucl Med 2018;59(9):1437-1444.
Spetsieris P, Ma Y, Peng S, et al. Identification of disease-related spatial covariance patterns using neuroimaging data. J Vis Exp 2013;76:50319. https://doi.org/10.3791/50319
Eidelberg D. Metabolic brain networks in neurodegenerative disorders: a functional imaging approach. Trends Neurosci 2009;32(10):548-557.
Teune LK, Renken RJ, Mudali D, et al. Validation of parkinsonian disease-related metabolic brain patterns. Mov Disord 2013;28(4):547-551.
Meles SK, Renken RJ, Pagani M, et al. Abnormal pattern of brain glucose metabolism in Parkinson's disease: replication in three European cohorts. Eur J Nucl Med Mol Imaging 2020;47(2):437-450.
Holtbernd F, Gagnon JF, Postuma RB, et al. Abnormal metabolic network activity in REM sleep behavior disorder. Neurology 2014;82(7):620-627.
Schindlbeck KA, Eidelberg D. Network imaging biomarkers: insights and clinical applications in Parkinson's disease. Lancet Neurol 2018;17(7):629-640.
Kogan RV, Janzen A, Meles SK, et al. Four-year follow-up of [18F]Fluorodeoxyglucose positron emission tomography-based Parkinson's disease-related pattern expression in 20 patients with isolated rapid eye movement sleep behavior disorder shows prodromal progression. Mov Disord 2021;36(1):230-235.
Orimo S, Suzuki M, Inaba A, Mizusawa H. 123I-MIBG myocardial scintigraphy for differentiating Parkinson's disease from other neurodegenerative parkinsonism: a systematic review and meta-analysis. Parkinsonism Relat Disord 2012;18(5):494-500.
Miyamoto T, Miyamoto M, Suzuki K, Nishibayashi M, Iwanami M, Hirata K. 123I-MIBG cardiac scintigraphy provides clues to the underlying neurodegenerative disorder in idiopathic REM sleep behavior disorder. Sleep 2008;31(5):717-723.
Sakakibara R, Tateno F, Aiba Y, et al. MIBG myocardial Scintigraphy identifies premotor PD/DLB during a negative DAT scan period: second report. Mov Disord Clin Pract 2019;6(1):46-50.
Knudsen K, Fedorova TD, Hansen AK, et al. In-vivo staging of pathology in REM sleep behaviour disorder: a multimodality imaging case-control study. Lancet Neurol 2018;17(7):618-628.
Iijima M, Osawa M, Momose M, et al. Cardiac sympathetic degeneration correlates with olfactory function in Parkinson's disease. Mov Disord 2010;25(9):1143-1149.
Mizutani Y, Nakamura T, Okada A, et al. Hyposmia and cardiovascular dysautonomia correlatively appear in early-stage Parkinson's disease. Parkinsonism Relat Disord 2014;20(5):520-524.
Mahlknecht P, Pechlaner R, Boesveldt S, et al. Optimizing odor identification testing as quick and accurate diagnostic tool for Parkinson's disease. Mov Disord 2016;31(9):1408-1413.
Gagnon JF, Postuma RB, Joncas S, Desjardins C, Latreille V. The Montreal cognitive assessment: a screening tool for mild cognitive impairment in REM sleep behavior disorder. Mov Disord 2010;25(7):936-940.
Movement Disorder Society Task Force on Rating Scales for Parkinson's Disease. The unified Parkinson's disease rating scale (UPDRS): status and recommendations. Mov Disord 2003;18(7):738-750.
McKeith IG, Ferman TJ, Thomas AJ, et al. Research criteria for the diagnosis of prodromal dementia with Lewy bodies. Neurology 2020;94(17):743-755.
Braak H, del Tredici K, Rüb U, de Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003;24(2):197-211.
Nihashi T, Ito K, Terasawa T. Diagnostic accuracy of DAT-SPECT and MIBG scintigraphy for dementia with Lewy bodies: an updated systematic review and Bayesian latent class model meta-analysis. Eur J Nucl Med Mol Imaging 2020;47(8):1984-1997.
Horsager J, Andersen KB, Knudsen K, et al. Brain-first versus body-first Parkinson's disease: a multimodal imaging case-control study. Brain 2020;143(10):3077-3088.
van der Zande JJ, Booij J, Scheltens P, Raijmakers PG, Lemstra AW. [(123)]FP-CIT SPECT scans initially rated as normal became abnormal over time in patients with probable dementia with Lewy bodies. Eur J Nucl Med Mol Imaging 2016;43(6):1060-1066.
Chahine LM, Brumm MC, Caspell-Garcia C, et al. Dopamine transporter imaging predicts clinically-defined α-synucleinopathy in REM sleep behavior disorder. Ann Clin Transl Neurol 2021;8(1):201-212.
Iranzo A, Valldeoriola F, Lomeña F, et al. Serial dopamine transporter imaging of nigrostriatal function in patients with idiopathic rapid-eye-movement sleep behaviour disorder: a prospective study. Lancet Neurol 2011;10(9):797-805.